Unknown

Dataset Information

0

Effector Mechanisms of CD8+ HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy.


ABSTRACT: Cytotoxic T lymphocyte (CTLs) activation is an independent predictor of response to neoadjuvant chemotherapy (NACT) in breast cancer (BC) patients. Here, we go deeper into the function of CD8+ HLA-DR+ T cells from NACT treated HER2 negative BC patients. Flow cytometry analysis revealed that CD8+ HLA-DR+ T cell percentage was increased in NACT responder (R) compared to non-responder (NR) patients. R patients with ER-/PR- hormone receptors had the highest CD8+ HLA-DR+ T cell frequencies, while no differences were found when patients were classified according to cancer stage or menopause status. Interestingly, the cytotoxicity and production of anti-tumor cytokines were enhanced when CD8+ HLA-DR+ T cells from healthy donors were cultured with plasma from R, but not from NR patients. The induced anti-tumor profile of CD8+ HLA-DR+ T cells was associated with plasmatic IL-12 and IFN-γ levels, increased cytokines in R patients. IL-12 or IFN-γ neutralization decreased cytotoxic activity and TNF-α production by cultured CD8+ HLA-DR+ T cells in R plasma presence. All these data suggest that an effective response to NACT in BC patients is associated with increased IL-12 or IFN-γ levels involved in the induction of cytotoxic and pro-inflammatory mechanisms in CD8+ HLA-DR+ T cells.

SUBMITTER: Osuna-Gomez R 

PROVIDER: S-EPMC8699550 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6282034 | biostudies-literature
| S-EPMC6794477 | biostudies-literature
| S-EPMC6245855 | biostudies-other
| S-EPMC8516689 | biostudies-literature
2015-06-12 | E-GEOD-32603 | biostudies-arrayexpress
| S-EPMC9334669 | biostudies-literature
| S-EPMC4079472 | biostudies-literature
| S-EPMC6534526 | biostudies-literature
2022-05-31 | GSE183768 | GEO
| S-EPMC6456717 | biostudies-literature